KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Debt to Equity (2016 - 2025)

Alnylam Pharmaceuticals' Debt to Equity history spans 8 years, with the latest figure at $0.52 for Q3 2025.

  • For Q3 2025, Debt to Equity changed N/A year-over-year to $0.52; the TTM value through Sep 2025 reached $0.52, changed N/A, while the annual FY2024 figure was $1.4, N/A changed from the prior year.
  • Debt to Equity reached $0.52 in Q3 2025 per ALNY's latest filing, up from $0.48 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.4 in Q4 2024 to a low of $0.48 in Q2 2025.
  • Average Debt to Equity over 3 years is $0.91, with a median of $1.02 recorded in 2025.
  • The largest YoY upside for Debt to Equity was 510.32% in 2021 against a maximum downside of 510.32% in 2021.
  • A 3-year view of Debt to Equity shows it stood at $1.15 in 2021, then grew by 21.69% to $1.4 in 2024, then crashed by 62.9% to $0.52 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Debt to Equity are $0.52 (Q3 2025), $0.48 (Q2 2025), and $1.02 (Q1 2025).